Cookie Policy

Mereo BioPharma Group plc's website uses cookies. By continuing to browse you are agreeing to our use of cookies. Find out more about our Cookie Policy.

MREO: US$3.92
logo.svg
  • About us
    About us
    • Overview
    • History
    • Our Leadership
    • Corporate Social Responsibility
    • Transparency Disclosure
    • Careers
    • Overview
    • History
    • Our Leadership
    • Corporate Social Responsibility
    • Transparency Disclosure
    • Careers
  • Pipeline
    Pipeline
    • Overview
    • Etigilimab (MPH-313)
    • Alvelestat (MPH-966)
    • Setrusumab (BPS-804)
    • Acumapimod (BCT-197)
    • Leflutrozole (BGS-649)
    • Navicixizumab (OMP-305B83)
    • Overview
    • Etigilimab (MPH-313)
    • Alvelestat (MPH-966)
    • Setrusumab (BPS-804)
    • Acumapimod (BCT-197)
    • Leflutrozole (BGS-649)
    • Navicixizumab (OMP-305B83)
  • Partners
    Partners
    • Overview
    • Partnering Contact
    • Current Partnerships
    • Overview
    • Partnering Contact
    • Current Partnerships
  • Investors
    Investors
    • Overview
    • Results, Reports and Presentations
    • NASDAQ
    • Investor Information
    • Corporate Governance
    • US Tax
    • Register for Email Alerts
    • Overview
    • Results, Reports and Presentations
    • NASDAQ
    • Investor Information
    • Corporate Governance
    • US Tax
    • Register for Email Alerts
  • News and Events
    News and Events
    • Overview
    • Events and Conferences
    • Press Releases
    • Overview
    • Events and Conferences
    • Press Releases
  • Contact Us
  • Home
  • Sitemap

Sitemap

About us

Our Mission

History

Our Leadership

  • Our Team
  • Our Board

Corporate Social Responsibility

Transparency Disclosure

Pipeline

Etigilimab (MPH-313)

Alvelestat (MPH-966)

Setrusumab (BPS-804)

Acumapimod (BCT-197)

Leflutrozole (BGS-649)

Navicixizumab (OMP-305B83)

Partners

Our Approach

Partnering Contact

Current Partnerships

Investors

Results, Reports and Presentations

NASDAQ

  • Share Data
  • SEC Filings
  • Whistleblower Services

Investor Information

  • Analyst Coverage
  • Investor Contacts and Advisers
  • FAQ
  • Registrar Services
  • Warning to Investors
  • AIM Delisting

Corporate Governance

  • Division of Responsibilities
  • Board Committees
  • Relationships with Stakeholders and Shareholders
  • Corporate Social Responsibility
  • Key Documents
  • Transparency Disclosure

US Tax

Register for Email Alerts

News and Events

Events and Conferences

Press Releases

Contact Us

Company

Transparency Disclosure

Our Business Model

Our Strategy

Mereo BioPharma COVID-19 Information

Subscribe to our email alerts
  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Sitemap
  • Urgent Medical Inquiries and Expanded Access
  • Careers
Mereo BioPharma Group plc © 2021